Pay in 4 interest-free payments of $6.47 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
A recent meta-analysis showed that patients with coexisting diabetes and HF have an increased risk of all-cause death, cardiovascular (CV) death and hospitalisation [6]
Tirzepatide maintenance: the SURMOUNT-4 evidence The SURMOUNT-4 trial used a randomized-withdrawal design: all participants took open-label tirzepatide for 36 weeks (reaching a mean weight reduction of about 20.9%), then were randomized either to continue the drug or switch to placebo for another 52 weeks
Now that GLP-1 receptor agonists have entered the market as injectable treatments, patients naturally assume all injectable diabetes medications work the same way
No follow-up protocol
US$ 22.48
US$ 26.78
US$ 25.25
